Clinical Trials Sponsored by Merck Sharp & Dohme LLC

Total 3975 results

Merck Sharp & Dohme LLC

Completed

Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)

Lymphoma
Merck Sharp & Dohme LLC

Completed

Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171)

Non-alcoholic Fatty Liver Disease (NAFLD)
Merck Sharp & Dohme LLC

Withdrawn

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

Dyslipidemia
Merck Sharp & Dohme LLC

Terminated

Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Terminated

A Study of MK0364 in Obese Patients (0364-014)

Obesity
Merck Sharp & Dohme LLC

Completed

A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)

Bladder Neoplasms
Merck Sharp & Dohme LLC

Terminated

Two-Part Study to Evaluate the Dose Response of SCH 527123 on Sputum Neutrophilia Following Ozone Challenge in Healthy Subjects and Chronic Obstructive Pulmonary Disease (COPD) Patients (P05567 AM7)

Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC

Completed

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Rosacea
Merck Sharp & Dohme LLC

Completed

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Melanoma | Renal Cell Carcinoma | Breast Cancer | Prostate Cancer | Bladder Carcinoma | Colon Carcinoma | Non-Small Cell Lung Carcinoma | Upper GI Tract Carcinoma
Merck Sharp & Dohme LLC

Completed

Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Terminated

MK0859 Dose-Ranging Study (0859-003)

Hypercholesterolemia | Mixed Hyperlipemia
Merck Sharp & Dohme LLC

Completed

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Chemotherapy-Induced Nausea and Vomiting (CINV)
Merck Sharp & Dohme LLC

Completed

Effect of Vicriviroc on HIV Ribonucleic Acid (RNA) Levels in Cerebrospinal Fluid (Study P05241)

HIV Infections
Merck Sharp & Dohme LLC

Terminated

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Diabetes Mellitus, Type 2
Merck Sharp & Dohme LLC

Completed

Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)

Neoplasms | Malignant
Merck Sharp & Dohme LLC

Completed

A Study in Adult and Pediatric Patients With Cystic Fibrosis

Cystic Fibrosis
Merck Sharp & Dohme LLC

Completed

A Study of a Bivalent Influenza Peptide Conjugate Vaccine in Healthy Adults

Influenza
Merck Sharp & Dohme LLC

Completed

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

Cancers Expressing HER-2 and/or CEA
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)

HIV Infections
Merck Sharp & Dohme LLC

Completed

Registry to Assess Long-term Outcome in HIV Subjects Who Participated in Phase 2 and 3 Clinical Trials Involving Vicriviroc (Study P04999) (COVER)

HIV Infections
Merck Sharp & Dohme LLC

Terminated

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Leukemia, Myeloid, Acute | Lymphoblastic Leukemia, Acute
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)

Hepatitis C | Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)

HIV Infections | HIV-1
Merck Sharp & Dohme LLC

Completed

MK3207 for Treatment of Acute Migraines (3207-005)

Migraine
Merck Sharp & Dohme LLC

Completed

A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)

Obesity
Merck Sharp & Dohme LLC

Completed

A Study of MK0657 in Parkinson's Disease Patients (0657-006)

Parkinson's Disease
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (NEXT-1)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

Cardiovascular Disease

United States
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Cervical Cancer | Genital Warts
Merck Sharp & Dohme LLC

Completed

MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

Aspergillosis
Merck Sharp & Dohme LLC

Completed

Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) (POMOSCH)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)

Breast Neoplasm
Merck Sharp & Dohme LLC

Completed

Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

Vomiting
Merck Sharp & Dohme LLC

Completed

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Bacterial Conjunctivitis

United States
Merck Sharp & Dohme LLC

Terminated

A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)

Posterior Blepharoconjunctivitis

United States
Merck Sharp & Dohme LLC

Completed

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Melanoma | Glioblastoma Multiforme | Recurrence of Solid Tumor
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis

Blepharitis

United States
Merck Sharp & Dohme LLC

Completed

Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers

Bacterial Infections | Eye Infections
Merck Sharp & Dohme LLC

Completed

Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers

Bacterial Infections | Eye Infections

United States
Merck Sharp & Dohme LLC

Completed

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Chronic Hepatitis C

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension

Hypertension
Merck Sharp & Dohme LLC

Not yet recruiting

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

Non-alcoholic Fatty Liver Disease | NAFLD | Nonalcoholic Steatohepatitis | Metabolic Dysfunction-associated Steatotic Liver Disease | Metabolic Dysfunction-associated Steatohepatitis
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018)

Hypercholesterolemia
Merck Sharp & Dohme LLC

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Crohn's Disease
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Primary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Australia, New Zealand

3

Subscribe